Company profile for Anocca

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity. Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of dise...
Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity. Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Forskargatan 20C 151 36 Södertälje
Telephone
Telephone
+46 (0)8 410 807 50
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250818046061/en/Anocca-Raises-SEK-440-Million-to-Advance-Clinical-Trial-Targeting-Pancreatic-Cancer

BUSINESSWIRE
18 Aug 2025

https://www.contractpharma.com/breaking-news/anocca-raises-46m-to-advance-clinical-trial-targeting-pancreatic-cancer/

CONTRACTPHARMA
18 Aug 2025

https://www.globenewswire.com/news-release/2025/07/31/3124964/0/en/MaxCyte-Announces-Strategic-Platform-Licensing-Agreement-with-Anocca-AB-to-Advance-TCR-T-Cell-Therapy-Pipeline.html

GLOBENEWSWIRE
31 Jul 2025

https://www.globenewswire.com/news-release/2025/03/17/3043419/0/en/Anocca-Announces-Authorisation-of-Clinical-Trial-Application-to-Start-First-In-Human-Trial-in-Advanced-Pancreatic-Cancer.html

GLOBENEWSWIRE
17 Mar 2025

https://www.globenewswire.com/news-release/2024/11/26/2987214/0/en/Anocca-Announces-Submission-of-Clinical-Trial-Application-for-Multi-asset-Trial-VIDAR-1-in-Advanced-Pancreatic-Cancer.html

GLOBENEWSWIRE
26 Nov 2024

https://www.globenewswire.com/news-release/2024/09/09/2942524/0/en/Anocca-Presents-Data-at-ESMO-Congress-on-Preclinical-Development-of-its-TCR-T-Cell-Therapies-for-Cancer.html

GLOBENEWSWIRE
09 Sep 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty